• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CX3CL1和D-二聚体水平在COVID-19合并慢性阻塞性肺疾病患者死亡风险分层中的预测作用

Predictive Role of CX3CL1 and D-dimer Levels in Mortality Risk Stratification for COPD Patients With COVID-19.

作者信息

Xue Jing, Liu Meimei, Liu Xin, Gao Na, Hao Wendong

机构信息

Department of Internal Medicine, Jingbian County Hospital of Traditional Chinese Medicine, Yulin, CHN.

Department of Respiratory and Critical Care Medicine, Yulin Hospital, the First Affiliated Hospital of Xi'an Jiaotong University, Yulin, CHN.

出版信息

Cureus. 2025 Jul 25;17(7):e88782. doi: 10.7759/cureus.88782. eCollection 2025 Jul.

DOI:10.7759/cureus.88782
PMID:40861638
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12375886/
Abstract

OBJECTIVE

In this retrospective study conducted at Yulin Hospital, the First Affiliated Hospital of Xi'an Jiaotong University (Yulin, SN, CHN), we aimed to investigate the predictive role of CX3CL1 and D-dimer for mortality in hospitalized chronic obstructive pulmonary disease (COPD) patients with COVID-19.

METHODS

Complete blood counts and inflammatory cytokine levels were collected at admission from hospitalized COPD patients with COVID-19 to explore the relationship between inflammatory parameters and mortality of COPD patients with COVID-19.

RESULTS

Compared to severe COPD with COVID-19 patients, circulating biomarkers of CX3CL1 (453.3 vs. 305.3 pg/mL,p<0.01) and D-dimer (1231.8 ng/mL vs. 680 ng/mL,p<0.01) were significantly elevated in critical illness participants. The C indices of inflammatory biomarkers CX3CL1 and D-dimer were 0.78 and 0.68, respectively. Furthermore, the prolonged illness of COPD patients with COVID-19 was associated with circulating inflammatory biomarkers of CX3CL1 (p=0.021) and D-dimer (p=0.041).

CONCLUSION

Circulating inflammatory biomarkers of CX3CL1 and D-dimer have shown the potential to predict mortality among COPD patients with severe COVID-19. Monitoring CX3CL1 and D-dimer levels could enhance clinical decision-making and risk stratification, potentially guiding more effective treatment strategies to improve patient outcomes.

摘要

目的

在西安交通大学第一附属医院榆林医院（中国陕西省榆林市）进行的这项回顾性研究中，我们旨在探讨CX3CL1和D - 二聚体对住院的新冠肺炎慢性阻塞性肺疾病（COPD）患者死亡率的预测作用。

方法

收集新冠肺炎COPD住院患者入院时的全血细胞计数和炎症细胞因子水平，以探讨炎症参数与新冠肺炎COPD患者死亡率之间的关系。

结果

与新冠肺炎重度COPD患者相比，危重症患者循环生物标志物CX3CL1（453.3 vs. 305.3 pg/mL，p<0.01）和D - 二聚体（1231.8 ng/mL vs. 680 ng/mL，p<0.01）显著升高。炎症生物标志物CX3CL1和D - 二聚体的C指数分别为0.78和0.68。此外，新冠肺炎COPD患者病程延长与循环炎症生物标志物CX3CL1（p = 0.021）和D - 二聚体（p = 0.041）有关。

结论

CX3CL1和D - 二聚体的循环炎症生物标志物已显示出预测重度新冠肺炎COPD患者死亡率的潜力。监测CX3CL1和D - 二聚体水平可加强临床决策和风险分层，可能指导更有效的治疗策略以改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf1/12375886/eb624ce2faad/cureus-0017-00000088782-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf1/12375886/a63dcdc695f0/cureus-0017-00000088782-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf1/12375886/eb624ce2faad/cureus-0017-00000088782-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf1/12375886/a63dcdc695f0/cureus-0017-00000088782-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf1/12375886/eb624ce2faad/cureus-0017-00000088782-i02.jpg

相似文献

1
Predictive Role of CX3CL1 and D-dimer Levels in Mortality Risk Stratification for COPD Patients With COVID-19.CX3CL1和D-二聚体水平在COVID-19合并慢性阻塞性肺疾病患者死亡风险分层中的预测作用
Cureus. 2025 Jul 25;17(7):e88782. doi: 10.7759/cureus.88782. eCollection 2025 Jul.
2
Assessment of the relationship between hematologic parameters, (CPD), in screening for COVID-19 severity in women.评估血液学参数（CPD）与女性新冠病毒疾病严重程度筛查之间的关系。
Future Sci OA. 2025 Dec;11(1):2540749. doi: 10.1080/20565623.2025.2540749. Epub 2025 Aug 2.
3
Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2.常规实验室检测对预测 SARS-CoV-2 感染者死亡和病情恶化为重症或危重症 COVID-19 的准确性。
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015050. doi: 10.1002/14651858.CD015050.pub2.
4
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者自我管理干预措施（包括针对病情加重的行动计划）与常规护理的比较。
Cochrane Database Syst Rev. 2017 Aug 4;8(8):CD011682. doi: 10.1002/14651858.CD011682.pub2.
5
COVID-19 Organ Injury Pathology and D-Dimer Expression Patterns: A Retrospective Analysis.新型冠状病毒肺炎器官损伤病理学与D-二聚体表达模式：一项回顾性分析
Diagnostics (Basel). 2025 Jul 24;15(15):1860. doi: 10.3390/diagnostics15151860.
6
Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.噻托溴铵与长效β受体激动剂治疗稳定期慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009157. doi: 10.1002/14651858.CD009157.pub2.
7
Vitamin D for the management of chronic obstructive pulmonary disease.维生素D用于慢性阻塞性肺疾病的管理
Cochrane Database Syst Rev. 2024 Sep 27;9(9):CD013284. doi: 10.1002/14651858.CD013284.pub2.
8
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.慢性阻塞性肺疾病成人患者的预防性抗生素治疗：一项网络荟萃分析。
Cochrane Database Syst Rev. 2021 Jan 15;1(1):CD013198. doi: 10.1002/14651858.CD013198.pub2.
9
Self-management interventions for people with chronic obstructive pulmonary disease.针对慢性阻塞性肺疾病患者的自我管理干预措施。
Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4.
10
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病自我管理的计算机和移动技术干预措施。
Cochrane Database Syst Rev. 2017 May 23;5(5):CD011425. doi: 10.1002/14651858.CD011425.pub2.

本文引用的文献

1
Serum cystatin C and inflammatory factors related to COVID-19 consequences.血清胱抑素 C 与 COVID-19 后果相关的炎症因子。
BMC Infect Dis. 2023 May 22;23(1):339. doi: 10.1186/s12879-023-08258-0.
2
D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia.入住 ICU 时 D-二聚体、CRP、PCT 和 IL-6 水平可预测 COVID-19 肺炎患者的住院死亡率。
Oxid Med Cell Longev. 2022 Feb 28;2022:8997709. doi: 10.1155/2022/8997709. eCollection 2022.
3
Cystatin C, COVID-19 severity and mortality: a systematic review and meta-analysis.
胱抑素 C、COVID-19 严重程度和死亡率：系统评价和荟萃分析。
J Nephrol. 2022 Jan;35(1):59-68. doi: 10.1007/s40620-021-01139-2. Epub 2021 Aug 14.
4
Increased chemokines levels in patients with chronic obstructive pulmonary disease: correlation with quantitative computed tomography metrics.慢性阻塞性肺疾病患者趋化因子水平升高：与定量计算机断层扫描指标的相关性。
Br J Radiol. 2021 Feb 1;94(1118):20201030. doi: 10.1259/bjr.20201030. Epub 2020 Nov 25.
5
SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients.严重急性呼吸综合征冠状病毒 2 细胞进入受体血管紧张素转换酶 2 介导的内皮功能障碍导致 COVID-19 患者血管血栓形成。
Med Hypotheses. 2020 Dec;145:110320. doi: 10.1016/j.mehy.2020.110320. Epub 2020 Sep 30.
6
D-Dimer Concentrations and COVID-19 Severity: A Systematic Review and Meta-Analysis.D-二聚体浓度与新冠病毒疾病严重程度：一项系统评价与荟萃分析
Front Public Health. 2020 Aug 4;8:432. doi: 10.3389/fpubh.2020.00432. eCollection 2020.
7
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19.COVID-19 患者的入院 D-二聚体水平、D-二聚体趋势和结局。
Thromb Res. 2020 Dec;196:99-105. doi: 10.1016/j.thromres.2020.08.032. Epub 2020 Aug 20.
8
Comorbidity and its Impact on Patients with COVID-19.合并症及其对COVID-19患者的影响。
SN Compr Clin Med. 2020;2(8):1069-1076. doi: 10.1007/s42399-020-00363-4. Epub 2020 Jun 25.
9
COVID-19 and comorbidities: Deleterious impact on infected patients.COVID-19 与合并症：对感染患者的有害影响。
J Infect Public Health. 2020 Dec;13(12):1833-1839. doi: 10.1016/j.jiph.2020.07.014. Epub 2020 Aug 4.
10
Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉 2019 年新型冠状病毒感染患者家族聚集性的临床特征。
Virus Res. 2020 Sep;286:198043. doi: 10.1016/j.virusres.2020.198043. Epub 2020 Jun 2.